News | June 02, 2009

Minimally Invasive Stent Treatment Aids Chronic Venous Insufficiency

June 2, 2009 – During their report Friday at the 63rd Annual Meeting of the Society for Vascular Surgery, Seshadri Raju, M.D., FACS, and other researchers from the University of Mississippi in Jackson offered details about how many patients with severe symptoms of chronic venous insufficiency (CVI) often can be treated with newer, minimally invasive stent treatment without surgery.

Venous return from the lower limbs may be affected when major veins are obstructed (stenosis or occlusion) or when venous valves malfunction, allowing abnormal reverse flow (reflux). When this happens, CVI can occur. Also contributing to the development of CVI can be being overweight or pregnant, lack of exercise, or standing or sitting for a long time without much leg movement. Elderly patients who are sedentary and prone to relative immobility are susceptible to the development of CVI. Symptoms of CVI can include leg pain or tightness, swelling, or skin eczema and ulcers, which require treatment.

Traditionally, treatment has largely focused on reducing or eliminating reflux. Refluxive superficial veins can be stripped or treated by laser therapy. When deep veins are reflexive, symptoms are often more severe. Removal of refluxive deep veins is not possible and is prohibited. Correction of reflux in deep veins requires complex open surgery, which is available only in a few specialty centers and therefore not widely available.

Valve reflux can develop from idiopathic causes or because they were damaged by previous blood clots. Chronic venous obstruction commonly develops when previous blood clots change to fibrous (scar) tissue. Venous obstruction also can be caused by mechanisms other than blood clots but this is thought to be relatively rare.

According to Dr. Raju, intravascular ultrasound (IVUS) has found that obstructive deep vein lesions are found in more than 90 percent of CVI patients with severe symptoms. In roughly half of the cases, the cause of obstruction was prior blood clots and in the other half nonthrombotic mechanisms previously thought to be relatively rare as etiology. Deep valve reflux is commonly present as well in both types of obstruction.

During their report they said CVI can be treated with stents alone. This outpatient procedure incorporates stent placement in iliac veins via a catheter introduced through a needle stick in a thigh vein. The iliac veins are major venous drainage pathways from the lower limbs and are important sources of deep venous obstruction. During the study, researchers reviewed 1,487 CVI cases treated by venous stents in iliac veins using IVUS for diagnosis and stent placement. The study focused on 513 of these limbs that had associated reflux in deep veins.

"This research is a basis for a new paradigm in the treatment of CVI," said Dr. Raju. "Clinical results were impressive after stent placement alone and symptoms were so greatly relieved that further correction of the refluxing valves was not found to be necessary. Complete relief of pain was noticed in 83 percent of patients, which was sustained long-term (six years). Also at six years, swelling disappeared in 46 percent of patients and was improved significantly in an additional 25 percent of patients. A total of 63 percent of leg ulcers remained healed at five years after the procedure and quality of life measures also were improved."

He added that CVI is widely prevalent and is estimated to be three times as common as PAD. It affects all age groups and both sexes though more common in women.

"Although seldom limb or life threatening, chronic venous insufficiency is a significant cause of discomfort and disability," said Dr. Raju. "Work loss (working age population more often affected than PAD) and health care expenditures in treating the chronic condition is estimated to be substantial in Western countries. Patients with leg ulcers resulting from the CVI is a significant fraction of all patients treated in wound care centers. Because of its relative simplicity, stent technology is expected to be more widely available than complex open repair techniques benefiting a larger fraction of affected patients."

For more information: www.vascularsociety.org

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init